Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration.
Ronald Danis, Megan M McLaughlin, Michael Tolentino, Giovanni Staurenghi, Li Ye, Chun-Fang Xu, Robert Y Kim, Mark W Johnson, undefined Pazopanib Eye Drops Study Group
Br J Ophthalmol | BMJ | Published : 2014
AIMS: To evaluate pazopanib eye drops in patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration. METHODS: 70 patients with minimally classic or occult subfoveal choroidal neovascularisation were randomly assigned to 5 mg/mL TID, 2 mg/mL TID, and 5 mg/mL QD pazopanib eye drops for 28 days in a multicentre, double-masked trial with an optional safety extension for up to 5 additional months. The primary outcomes were central retinal thickness (CRT) and best-corrected visual acuity (BCVA) at Day 29. RESULTS: No significant decrease from baseline in CRT was observed overall; however, an exploratory analysis showed improvement in CRT (mean decrease of 89..View full abstract